Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 5/20 | 0.43 |
| ▸ | PPARA | Q07869 | 5/20 | 0.43 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.38 |
| ▸ | TYR | P14679 | 1/20 | 0.38 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6965661 | 0.91 | PPARG (0.42) | PPARGPPARAFFAR1PTGS1 | |
| SCHEMBL6960012 | 0.91 | PPARG (0.42) | PPARGPPARAFFAR1PTGS1PTPN11 | |
| SCHEMBL6958646 | 0.87 | PPARG (0.42) | PPARGPPARAMAPTFFAR1PTGS1 | |
| SCHEMBL6966158 | 0.85 | PPARA (0.41) | PPARGPPARAFFAR1 | |
| SCHEMBL6959235 | 0.83 | PPARG (0.35) | PPARGPPARAPTGS1PTPN11 | |
| SCHEMBL6958781 | 0.82 | PPARG (0.38) | PPARGPPARAMAPTPTGS1 | |
| SCHEMBL6966942 | 0.82 | PPARG (0.38) | PPARGPPARAMAPTFFAR1PTGS1 | |
| SCHEMBL6964983 | 0.82 | PPARG (0.34) | PPARGPPARAFFAR1PTGS1 | |
| SCHEMBL6958967 | 0.81 | PPARG (0.44) | PPARGPPARAPOLBMAPTFFAR1 | |
| SCHEMBL6967228 | 0.80 | PPARG (0.36) | PPARGPPARAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6579871-B2 | Phenyl oxazoles or thiazoles | ELI LILLY AND COMPANY | 2003-06-17 | — | — | US | disclosed |
| EP-0971709-B1 | NOVEL COMPOUNDS USEFUL AS NEURO-PROTECTIVE AGENTS | LILLY CO ELI (US) | 2003-05-21 | — | — | EP | disclosed |
| US-20030050311-A1 | Methods of using novel compounds as neuro-protective agents | PANETTA JILL ANN (US) | 2003-03-13 | — | — | US | disclosed |
| US-20020177595-A1 | Novel compounds useful as neuro-protective agents | PANETTA JILL ANN (US) | 2002-11-28 | — | — | US | disclosed |
| US-6472387-B1 | Methods of using compounds as neuro-protective agents | ELI LILLY AND COMPANY | 2002-10-29 | — | — | US | disclosed |
| US-6448396-B2 | 2-((3,5-DIALKYL-4-HYDROXYPHENYL-4-(2-(AMINOALKYLPHENOXY)ETHYL) OXAZOLES; ANTIISCHEMIC AGENTS; REPERFUSION INJURY OF PERIPHERAL ORGANS; FREE RADICAL ANTAGONISTS; PARKINSON'S AND ALZHEIMER'S DISESES; DOWN'S SYNDROME; AMYOTROPHIC LATERAL S. | ELI LILLY AND COMPANY | 2002-09-10 | — | — | US | disclosed |
| US-6423709-B1 | FOR THERAPY OF ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, AMYTROPHIC LATERAL SCLEROSIS OR CEREBRAL TRAUMA IN A MAMMAL | ELI LILLY AND COMPANY | 2002-07-23 | — | — | US | disclosed |
| US-20020065274-A1 | METHODS OF USING NOVEL COMPOUNDS AS NEURO-PROTECTIVE AGENTS | PANETTA JILL ANN (US) | 2002-05-30 | — | — | US | disclosed |
| US-6380213-B1 | PHENYL OXAZOLES, THIAZOLES, OXAZOLINES, OXADIAZOLES AND BENZOXAZOLES | ELI LILLY AND COMPANY | 2002-04-30 | — | — | US | disclosed |
| US-20010027194-A1 | NOVEL COMPOUNDS USEFUL AS NEURO-PROTECTIVE AGENTS | ELI LILLY AND COMPANY | 2001-10-04 | — | — | US | disclosed |
| US-5952360-A | Method for treating neuropathic pain | ELI LILLY AND COMPANY (US) | 1999-09-14 | — | — | US | disclosed |
| US-5942530-A | Method for treating pain | ELI LILLY AND COMPANY (US) | 1999-08-24 | — | — | US | disclosed |
| WO-1999018091-A1 | NOVEL COMPOUNDS USEFUL AS NEURO-PROTECTIVE AGENTS | ELI LILLY AND COMPANY (US) | 1999-04-15 | — | — | WO | disclosed |
| EP-0908186-A2 | Method for treating pain | ELI LILLY AND COMPANY (US) | 1999-04-14 | — | — | EP | disclosed |
| EP-0908454-A2 | Oxazoles, thiazoles, oxazolines, oxadiazoles and benzoxazoles useful as neuro-protective agents | ELI LILLY AND COMPANY (US) | 1999-04-14 | — | — | EP | disclosed |
| EP-0908180-A2 | Use of phenyl oxazole or phenyl thiazole derivatives for treating pain | ELI LILLY AND COMPANY (US) | 1999-04-14 | — | — | EP | disclosed |
| EP-0906755-A2 | Use of phenyl oxazole or phenyl thiazole derivatives for treating neuropathic pain | ELI LILLY AND COMPANY (US) | 1999-04-07 | — | — | EP | disclosed |
| WO-1999009829-A1 | METHOD FOR TREATING PAIN | ELI LILLY AND COMPANY (US) | 1999-03-04 | — | — | WO | disclosed |
| WO-1999009980-A1 | METHOD FOR TREATING PAIN | ELI LILLY AND COMPANY (US) | 1999-03-04 | — | — | WO | disclosed |
| WO-1999009979-A1 | METHOD FOR TREATING NEUROPATHIC PAIN | ELI LILLY AND COMPANY (US) | 1999-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010027194-A1 | NOVEL COMPOUNDS USEFUL AS NEURO-PROTECTIVE AGENTS | NLN, PRDX5, TXN2 | PPARG 458/4885PPARA 471/4885TRIM24 1986/4885 |
| US-20020177595-A1 | Novel compounds useful as neuro-protective agents | NLN, PRDX5, TXN2 | PPARG 458/4885PPARA 471/4885TRIM24 1986/4885 |
| US-20020065274-A1 | METHODS OF USING NOVEL COMPOUNDS AS NEURO-PROTECTIVE AGENTS | NLN, GAP43, TXN2 | PPARG 888/4885PPARA 902/4885TRIM24 2606/4885 |
| US-20030050311-A1 | Methods of using novel compounds as neuro-protective agents | NLN, GAP43, TXN2 | PPARG 888/4885PPARA 902/4885TRIM24 2606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.